Glenmark Pharma Gets USFDA Approval for Seizure Drug
By Rediff Money Desk, New Delhi Jul 17, 2024 09:47
Glenmark Pharmaceuticals has received USFDA approval for its generic Topiramate capsules used to treat seizures. The drug is bioequivalent to Topamax capsules.
![Glenmark Pharma Gets USFDA Approval for Seizure Drug](https://im.rediff.com/money/2012/oct/28drug.jpg)
New Delhi, Jul 17 (PTI) Glenmark Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic Topiramate capsules used to treat certain types of seizure.
The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement.
Glenmark's Topiramate capsules USP, 15 mg and 25 mg have been determined by the FDA to be bioequivalent and therapeutically equivalent to Topamax capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the US by Glenmark Pharmaceuticals Inc., USA, it added.
Topamax Capsules, 15 mg and 25 mg market achieved annual sales of approximately USD 21.9 million, the company said citing IQVIATM sales data for the 12-month period ended May 2024.
The company said its current portfolio consists of 198 products authorised for distribution in the US marketplace and 50 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA.
The company said it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The approval by the US Food & Drug Administration (USFDA) is for Topiramate capsules of strengths 15 mg and 25 mg, Glenmark Pharmaceuticals said in a statement.
Glenmark's Topiramate capsules USP, 15 mg and 25 mg have been determined by the FDA to be bioequivalent and therapeutically equivalent to Topamax capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the US by Glenmark Pharmaceuticals Inc., USA, it added.
Topamax Capsules, 15 mg and 25 mg market achieved annual sales of approximately USD 21.9 million, the company said citing IQVIATM sales data for the 12-month period ended May 2024.
The company said its current portfolio consists of 198 products authorised for distribution in the US marketplace and 50 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA.
The company said it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![ADB Retains...](https://im.rediff.com/80-80/money/2022/sep/01economy1.jpg)
ADB Retains India's FY25 Growth at 7%: Monsoon...
The Asian Development Bank (ADB) maintains India's GDP growth forecast at 7% for FY25,...
![Suzuki Tech...](https://im.rediff.com/80-80/money/2022/mar/20suzuki.jpg)
Suzuki Tech Strategy: Light Vehicles, Small...
Suzuki outlines its technology strategy for the next 10 years, focusing on light...
![Glenmark Pharma...](https://im.rediff.com/80-80/money/2012/oct/28drug.jpg)
Glenmark Pharma Gets USFDA Approval for Seizure...
Glenmark Pharmaceuticals has received USFDA approval for its generic Topiramate...